Publication date: Jan 01, 2023 Hotspot mutations of the BRAF and NRAS genes are the most common genetic alterations in invasive cutaneous melanoma; however, the prognostic significance of BRAF and ... Read more

Publication date: Dec 08, 2022 Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable ... Read more

Publication date: Dec 07, 2022 The purpose of this systematic review was to examine the timing and patterns of recurrence for patients with regionally metastatic melanoma on the basis of ... Read more

Publication date: Dec 07, 2022 Acral melanoma (AM) and mucosal melanomas (MM) are rare clinical subtypes of melanoma. AM and MM are etiologically, biologically, and molecularly distinct from cutaneous melanoma ... Read more

Publication date: Dec 07, 2022 Hyperthermia using magnetic nanoparticles enables tumor-specific heating and can destroy tumor tissues. This approach works as in situ vaccination with tumor antigens released from dying ... Read more

Publication date: Dec 07, 2022 Cutaneous melanoma is one of the most aggressive forms of skin cancer, with the development of advanced stage disease resulting in a high rate of ... Read more

Publication date: Jan 01, 2023 Benefit for clinical melanoma treatments, the transdermal neoadjuvant therapy could reduce surgery region and increase immunotherapy efficacy. Using lipoplex (Lipo-PEG-PEI-complex, LPPC) encapsulated doxorubicin (DOX) and ... Read more

Publication date: Dec 07, 2022 Concepts Keywords Biopsies Metastasis Dermatol Tumor-infiltrating lymphocytes Drugs RTT Therapy Melanoma Tumor Oncology Medical specialties Cancer Medicine Tumor Checkpoint inhibitor Draft:DermTech Semantics Type Source Name ... Read more

Publication date: Dec 07, 2022 This study aimed to explore the mechanism of parthenolide in inhibiting melanoma metastasis through network pharmacology and cell experiment. This research obtained the targets of ... Read more

Publication date: Dec 07, 2022 This study aimed to identify baseline clinical features associated with the outcomes of patients enrolled in the COMBI-MB phase II study of dabrafenib and trametinib ... Read more